Healthcare utilization and costs associated with tyrosine kinase inhibitor switching in patients with chronic myeloid leukemia

作者：Kropf Patricia; Barnes Gisoo^*; Tang Boxiong; Pathak Ashutosh; Issa Jean Pierre J

来源：Leukemia and Lymphoma, 2016, 57(4): 935-941.

DOI：10.3109/10428194.2015.1088654

• burden
• treatment failure
• Tyrosine kinase inhibitors
• chronic myeloid leukemia
• costs
• healthcare resource utilization
• switching

Differences in healthcare utilization and costs were examined in chronic myeloid leukemia (CML) patients experiencing first-, second- and third-line tyrosine kinase inhibitor (TKI) therapy. Three CML cohorts were identified from the Truven Health MarketScan (R) database: No-Switch Cohort (NSc) = did not switch from first-line; One-Switch Cohort (OSc) = switched from first- to second-line only; Two-Switch Cohort (TSc) = switched to second- and then third-line. A total of 3510 patients were identified (mean = 54%; age = 55.8 years). NSc comprised 81% of the sample, OSc comprised 15% and 4% were in the TSc. First-line utilization/costs were significantly higher in the OSc/TSc compared to the NSc. Second-line hospital/outpatient visits and costs were higher in TSc compared to OSc. TSc experienced a significant cost increase from first- to second-line ($4226.46), twice that of OSc ($2488.03). TKI switching is associated with a substantial increase in healthcare utilization and costs, particularly for patients who switch twice.

• 出版日期2016-4-2